OptiMedica

About OptiMedica

OptiMedica Corp. operated as a medical device company with a strategic focus on ophthalmic technologies. Founded in 2004 and based in Santa Clara, California, the firm initially targeted retinal and glaucoma conditions, achieving a significant milestone with the development of the PASCAL® (Pattern Scan Laser) Method of retinal photocoagulation. This technology, co-invented by ophthalmic thought leader Dr. Mark Blumenkranz and four Silicon Valley engineers, offered a semi-automated pattern generation technique for rapid and precise laser pulse delivery. The commercial success of the PASCAL system, which included several models and sold over 600 units, culminated in the sale of this entire business line to Topcon Corp. in August 2010.

Following this divestiture, OptiMedica pivoted its entire operation to concentrate on the cataract surgery market. This strategic shift was backed by prominent venture capital firms including Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners, and Bio*One Capital. The company's efforts resulted in the creation of the Catalys® Precision Laser System, a sophisticated platform designed to replace demanding manual steps in cataract surgery with image-guided femtosecond laser technology. The Catalys system integrates a femtosecond laser, 3D Optical Coherence Tomography (OCT) imaging, and proprietary pattern scanning technology. Key features included the Liquid Optics™ Interface, which used a fluid medium to ensure a stable and non-distorting connection to the patient's eye, and an Integral Guidance™ system for precise laser delivery.

The business model centered on the development and sale of these high-value capital equipment systems to ophthalmic surgeons and specialized eye care centers. The Catalys system received CE Mark approval in Europe and FDA clearance in the U.S., enabling its commercial launch in late 2011 and early 2012, respectively. The company's trajectory concluded in August 2013, when it was acquired by Abbott for its Abbott Medical Optics division in a deal valued at an initial $250 million, with up to $150 million in additional milestone payments. This acquisition marked Abbott's entry into the femtosecond laser-assisted cataract surgery market, integrating OptiMedica's technology into its broader portfolio of vision care products.